Shilpa Medicare Ltd.

NSE: SHILPAMED BSE: 530549 SECTOR: Pharmaceuticals & Drugs  30k   157   20

281.45
-3.30 (-1.16%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 286.05

Today's Low

₹ 280

52 Week High

₹ 606

52 Week Low

₹ 272

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2443.04 Cr.

Enterprise Value

2621.24 Cr.

No. of Shares

8.68 Cr.

P/E

135.38

P/B

1.14

Face Value

₹ 1

Div. Yield

0.39 %

Book Value (TTM)

₹  247.51

CASH

15.83 Cr.

DEBT

194.03 Cr.

Promoter Holding

50.01 %

EPS (TTM)

₹  2.08

Sales Growth

38.86%

ROE

1.09 %

ROCE

1.61%

Profit Growth

-69.03 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year38.86%
3 Year-18.68%
5 Year-13.42%

Profit Growth

1 Year-23.54%
3 Year4.34%
5 Year2.04%

ROE%

1 Year1.09%
3 Year6.49%
5 Year8.37%

ROCE %

1 Year1.61%
3 Year6.9%
5 Year9%

Debt/Equity

0.0939

Price to Cash Flow

14.05

Interest Cover Ratio

4.03590836794203

CFO/PAT (5 Yr. Avg.)

1.10367071316617

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2022 50.01 0.81
Jun 2022 50.01 0.81
Mar 2022 50.01 0.81
Dec 2021 50.01 0.81
Sep 2021 53.25 0.81
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 459.3916 Cr.
  • Company is virtually debt free.
  • The company has a good cash flow management; CFO/PAT stands at 1.10367071316617.
  • The company has a high promoter holding of 50.01%.

 Limitations

  • The company has shown a poor profit growth of -45.4383753583575% for the Past 3 years.
  • The company has shown a poor revenue growth of -18.6844522118901% for the Past 3 years.
  • Company has a poor ROE of 6.48870797155553% over the past 3 years.
  • The company is trading at a high PE of 135.38.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
Net Sales 91.25 276.64 72.87 60.83 68.73
Total Expenditure 88.13 220.1 74.42 56.33 93.21
Operating Profit 3.12 56.54 -1.55 4.5 -24.48
Other Income 8.88 13 10.34 12.63 18.09
Interest 3.15 6.6 1.73 2.66 4.92
Depreciation 8.36 14.61 10.29 10.42 11.89
Exceptional Items 8.91 0 -0.1 0 -0.59
Profit Before Tax 9.39 48.34 -3.34 4.05 -23.78
Tax -0.67 11.58 -0.39 0.2 -4.16
Profit After Tax 10.06 36.76 -2.95 3.85 -19.63
Adjusted EPS (Rs) 1.23 4.24 -0.34 0.44 -2.26

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 741.29 663.88 805.97 257.05 356.95
Total Expenditure 573.43 494.86 568.18 228.58 345.92
Operating Profit 167.86 169.02 237.79 28.47 11.03
Other Income 34.52 17.16 40.02 37.14 51.52
Interest 2.12 2.79 4.33 6.07 9.05
Depreciation 32.78 34.01 34.96 22.28 34.82
Exceptional Items 0 6.22 -4.54 52.95 8.8
Profit Before Tax 167.49 155.6 233.99 90.21 27.49
Tax 34.25 31.49 40.27 25.12 7.33
Net Profit 133.24 124.11 193.72 184.39 140.99
Adjusted EPS (Rs.) 16.34 15.22 23.76 7.98 2.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 8.15 8.15 8.15 8.15 8.68
Total Reserves 1148.83 1273.39 1445.27 1629.68 2056.99
Borrowings 68.11 81.1 164.48 324.52 120.28
Other N/C liabilities 70.98 76.06 43.52 81.06 89.87
Current liabilities 251.05 229.59 359.86 473.98 161.65
Total Liabilities 1547.12 1668.29 2021.28 2517.39 2896.12
Assets
Net Block 488.69 510.84 517 640.9 565.78
Capital WIP 131 284.8 244.18 297.19 52.57
Intangible WIP 69.99 116.41 128.63 185.16 240.55
Investments 111.35 89.04 93.48 219.32 237.5
Loans & Advances 68.04 119.95 124.54 391.84 595.14
Other N/C Assets 24.83 26.83 5.76 3.1 895.15
Current Assets 653.22 520.42 907.69 779.9 309.44
Total Assets 1547.12 1668.29 2021.28 2517.39 2896.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 167.49 155.6 233.99 255.54 192.89
Adjustment 8.68 25.78 -5.39 -25.46 32.64
Changes in Assets & Liabilities -81.25 18.23 -57.95 -117.1 -17.17
Tax Paid -40.45 -35.45 -40.85 -43.34 -34.49
Operating Cash Flow 54.46 164.16 129.79 69.63 173.87
Investing Cash Flow -12.83 -214.71 -302.49 -238.13 -378.97
Financing Cash Flow -61.16 8.17 170.1 255.58 97.23
Net Cash Flow -19.53 -42.38 -2.59 87.08 -107.88

Corporate Actions

Investors Details

PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022% Sep 2022%
Promoters 53.25 50.01 50.01 50.01 50.01
vishnukant chaturb... 7.81 7.33 7.33 7.33 7.33
kantadevi inani 3.12 2.93 2.93 2.93 2.93
dharmavati bhutada 7.61 7.15 7.15 7.15 7.15
kamal kishore inani - - - - -
ravi kumar innani 4.91 4.62 4.62 4.62 4.62
suraj kumar innani 4.88 4.59 4.59 4.59 4.59
ramakant inani - - - - -
ramakant innani 4.29 4.03 1.73 1.73 1.73
shakuntalabai inani - - - - -
omprakash inani - - - - -
omprakash innani - - - - -
om prakash inani 3.52 3.30 3.30 3.30 3.30
deepak kumar innani 3.35 3.15 - 3.15 3.15
deepak kumar inani - - - - -
deepak kumar innan... - - 3.15 - -
kantadevi innani - - - - -
manjulatha inani - - - - -
brijgopal inani - - - - -
brijgopal innani 2.67 2.51 1.35 1.35 1.35
keshav bhutada 2.45 2.30 2.30 2.30 2.30
madhav vishnukant ... 2.45 2.30 2.30 2.30 2.30
madhav bhutada - - - - -
vishnukanth c bhut... 1.64 1.54 - - -
vishnukant c bhuta... - - - - -
vishnukanth c bhut... - - 1.54 1.54 1.54
taradevi innani 0.31 0.29 1.44 1.44 1.44
vishnukanta inani 0.26 0.24 1.40 1.40 1.40
natamal innani 1.39 1.30 1.30 1.30 1.30
shakuntalabai inna... 1.39 1.30 1.30 1.30 1.30
natmal inani - - - - -
ravi kumar inani - - - - -
priya inani - - - - -
suraj kumar inani - - - - -
keerti inani - - - - -
keshava bhutada - - - - -
sagar innani - - 1.15 1.15 1.15
triveni inani - - 0.34 0.34 0.34
triveni innani 0.36 0.34 - - -
taradevi inani - - - - -
vishnukanta innani - - - - -
vishnkanta inani - - - - -
priya innani 0.22 0.21 0.21 0.21 0.21
kamalkishore innani 0.20 0.19 0.19 0.19 0.19
kamal kishore inna... - - - - -
keerthi innani - - - - -
manjulatha innani 0.19 0.18 0.18 0.18 0.18
keerti innani 0.19 0.18 0.18 0.18 0.18
namrata bhutada 0.03 0.03 0.03 0.03 0.03
PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022% Sep 2022%
Investors 46.75 49.99 49.99 49.99 49.99
tano mauritius ind... - - - - -
tano mauritius ind... - - - - -
pivotal enterprise... 2.35 2.21 2.53 2.53 -
ta fii investors l... 3.71 3.48 3.48 3.48 -
ta fii investors f... - - - - -
reliance capital t... - - - - -
pivotal business m... 1.75 1.64 2.12 2.12 -
nippoin india trus... - - - - -
amal n parikh - - - - -
think india opport... - 2.02 2.02 2.02 2.02
blue daimond prope... - 1.84 1.84 - -
blue daimond prope... - - - 1.84 -
malabar select fund - 1.61 1.80 1.80 1.80
icici prudential b... - - - - -
amal n parikh - - - - -
malabar india fund... - 1.58 1.58 1.58 1.58
duro one investmen... - - - - -
baring india priva... - - - - -
nippon life india ... - - - - -
nippon life india ... 1.24 1.13 - - -
india opportunitie... 1.07 1.00 1.19 1.19 1.19
sundar iyer - - 1.15 1.15 1.15
anandkumar ramesh ... - - 1.06 1.08 1.08
quant mutual fund ... 1.04 - - - -
qib - - - - -
qualified institut... - - - - -
iepf 0.26 0.33 0.33 0.33 -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ4FY20 20 Jun 2020
  • PresentationQ3FY22 11 Feb 2022
  • PresentationQ1FY21 11 Aug 2020
  • PresentationQ4FY21 1 Jun 2021
  • PresentationQ4FY21 1 Jun 2021

Company News

Shilpa Medicare submits related party transactions24 Nov 2022, 10:51AM Shilpa Medicare informs about analyst meet 21 Nov 2022, 4:59PM Shilpa Medicare informs about disclosure21 Nov 2022, 2:20PM Shilpa Medicare - Quaterly Results11 Nov 2022, 5:10PM Shilpa Medicare - Quaterly Results11 Nov 2022, 5:10PM Shilpa Medicare informs about disclosure 27 Oct 2022, 4:28PM Shilpa Medicare informs about compliance certificate15 Oct 2022, 4:21PM Shilpa Medicare’s Analytical Services division gets USFDA’s clearance 22 Sep 2022, 5:26PM Shilpa Medicare gets CDSCO approval for hemostatic spray of Tranexamic Acid20 Sep 2022, 12:16PM Shilpa Medicare informs about approval for tablets16 Sep 2022, 3:14PM Shilpa Medicare gets USFDA’s nod for Tenofovir Alafenamide tablets16 Sep 2022, 2:29PM Shilpa Medicare informs about audio recording of conference call 25 Aug 2022, 12:19PM Shilpa Medicare’s arm completes Human Clinical studies of High concentration Biosimilar Adalimumab 19 Aug 2022, 4:00PM Shilpa Medicare - Quaterly Results11 Aug 2022, 6:46PM Shilpa Medicare - Quaterly Results11 Aug 2022, 6:46PM Shilpa Medicare’s Bengaluru unit clears USFDA remote record review29 Jul 2022, 4:42PM Shilpa Medicare gets GMP certificate from MOH-Russia for API facility in Karnataka18 Jul 2022, 10:01AM Shilpa Medicare gets GMP Certificate from UK MHRA for Bengaluru facility 12 Jul 2022, 4:57PM Shilpa Medicare executes transfer agreement with Shilpa Pharma Lifesciences4 Jul 2022, 9:22AM Shilpa Medicare - Quaterly Results23 May 2022, 4:35PM Shilpa Medicare - Quaterly Results23 May 2022, 4:35PM Shilpa Medicare - Quaterly Results23 May 2022, 4:35PM USFDA inspects Shilpa Medicare’s Analytical Services Division in Telangana2 May 2022, 4:30PM Shilpa Medicare gets NoC from RCGM for Biosimilar Aflibercept 26 Apr 2022, 10:49AM Shilpa Medicare informs about company updates25 Apr 2022, 2:33PM Shilpa Medicare informs about certificate23 Apr 2022, 4:09PM Shilpa Medicare informs about update2 Apr 2022, 4:16PM Shilpa Medicare informs about disclosure30 Mar 2022, 9:56AM Shilpa Medicare informs about press release11 Feb 2022, 4:14PM Shilpa Medicare’s arm, Mylab Discovery Solutions enter into strategic partnership11 Feb 2022, 3:28PM Shilpa Medicare - Quaterly Results8 Feb 2022, 3:42PM Shilpa Medicare - Quaterly Results8 Feb 2022, 3:42PM Shilpa Medicare - Quaterly Results8 Feb 2022, 3:42PM Shilpa Medicare gets nod from European Authorities for Pemetrexed Injection21 Jan 2022, 6:07PM Shilpa Medicare launches ‘Prucalshil’ Orally Disintegrating Strips21 Dec 2021, 2:08PM Shilpa Medicare informs about disclosure19 Nov 2021, 3:23PM Shilpa Medicare informs about disclosure17 Nov 2021, 12:32PM Shilpa Medicare informs about scrutinizer report and voting results11 Nov 2021, 10:56AM Shilpa Medicare enters Phase I Clinical Trial for its new biological entity1 Nov 2021, 12:28PM Shilpa Medicare informs about outcome of board meeting 29 Oct 2021, 4:59PM Shilpa Medicare ties up with Cadila Healthcare 24 Sep 2021, 2:40PM Shilpa Medicare gets DCGI approval for ‘2-Deoxy2-Glucose’31 Aug 2021, 3:39PM Shilpa Medicare informs about board meeting7 Aug 2021, 1:00PM Shilpa Medicare informs about updates28 Jul 2021, 12:51PM Shilpa Medicare gets nod to transfer API Business to WOS13 Jul 2021, 11:29AM Shilpa Medicare informs about annual secretarial compliance report26 Jun 2021, 12:46PM Shilpa Medicare gets approval to manufacture, sale of 2-Deoxy-D-Glucose25 Jun 2021, 11:14AM Shilpa Medicare launches pediatric dose Paracetamol Oral Thin Film22 Jun 2021, 10:59AM Shilpa Medicare submits related party transactions5 Jun 2021, 3:10PM Shilpa Medicare informs about audit report1 Jun 2021, 1:51PM

Shilpa Medicare Stock Price Analysis and Quick Research Report. Is Shilpa Medicare an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Shilpa Medicare and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 173.8697 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Shilpa Medicare has a Debt to Equity ratio of 0.0939 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Shilpa Medicare , the EPS growth was -70.9141690567739 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Shilpa Medicare has OPM of 3.09142578914016 % which is a bad sign for profitability.
     
  • ROE: Shilpa Medicare have a poor ROE of 1.0886135619236 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Shilpa Medicare

X